Skip to main content
    F

    Fulgent Genetics Inc (FLGT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.07
    -0.59 (-2.37%)

    Market Cap: $688.98M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Fulgent Genetics Inc (FLGT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Fulgent Genetics reported revenue of $322.67M for the fiscal year ended Dec 31, 2025, up 13.8% from the year before. That year, net income was -$61.63M with a net margin of -19.1%, operating cash flow was -$101.64M and free cash flow was -$124.21M. The quarter ended Sep 30, 2026 had revenue of $90.41M and net income of -$13.34M.

    Revenue and Margins

    The operating margin was -28.2% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $18.28M, a compound annual rate of 37.6%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$322.67M+13.8%40.6%-28.2%-19.1%
    Dec 2024$283.47M-2.0%37.8%-26.1%-15.5%
    Dec 2023$289.21M-53.3%36.1%-67.6%-60.6%
    Dec 2022$618.97M-37.6%59.3%28.8%22.9%
    Dec 2021$992.58M+135.4%78.3%68.1%51.0%
    Dec 2020$421.71M+1196.5%78.7%68.8%50.8%
    Dec 2019$32.53M+52.3%56.6%-1.3%-1.3%
    Dec 2018$21.35M+14.0%49.9%-23.7%-26.3%
    Dec 2017$18.73M+2.5%54.3%-18.6%-13.4%
    Dec 2016$18.28MN/A63.2%5.0%-29.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$322.67M$283.47M$289.21M$618.97M$992.58M$421.71M$32.53M$21.35M$18.73M$18.28M
    Cost of revenue$191.80M$176.25M$184.76M$252.07M$215.53M$89.81M$14.11M$10.70M$8.55M$6.72M
    Gross profit$130.88M$107.22M$104.46M$366.90M$777.05M$331.90M$18.42M$10.65M$10.18M$11.55M
    Research and development$53.91M$48.82M$41.44M$28.91M$24.22M$11.58M$6.54M$5.53M$4.22M$3.56M
    Operating income-$91.10M-$73.92M-$195.53M$178.53M$675.95M$290.16M-$428.00K-$5.07M-$3.48M$918.00K
    Net income-$61.63M-$43.82M-$175.24M$141.92M$506.24M$214.31M-$411.00K-$5.61M-$2.51M-$5.35M
    EBITDA-$81.85M-$64.05M-$172.98M$216.84M$694.55M$293.98M$1.78M-$2.61M-$1.38M$2.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$90.41M$85.39M$71.14M$83.34M$84.07M$81.80M$73.46M$76.21M$71.74M$71.03M$64.48M$70.50M
    Gross profit$31.95M$25.68M$21.49M$32.58M$35.51M$34.44M$28.35M$31.85M$26.77M$26.49M$22.10M$25.23M
    Operating income-$22.55M-$36.07M-$34.62M-$36.24M-$15.35M-$19.71M-$19.80M-$16.14M-$17.08M-$18.91M-$21.80M-$151.12M
    Net income-$13.34M-$29.72M-$25.27M-$23.65M-$6.83M-$19.26M-$11.90M-$6.19M-$14.69M-$9.09M-$13.85M-$134.33M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $2.43M by $47.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.21B$1.22B$1.24B$1.39B$1.28B$700.46M$88.76M$53.90M$57.18M$58.04M
    Current assets$550.49M$353.57M$507.85M$627.87M$611.96M$523.62M$37.08M$39.54M$32.93M$26.14M
    Cash and equivalents$50.19M$55.14M$97.47M$79.51M$164.89M$87.43M$11.96M$6.74M$6.49M$7.90M
    Total liabilities$106.81M$90.81M$102.04M$116.18M$112.84M$131.07M$5.98M$2.75M$3.01M$3.56M
    Short-term debt$476.00K$412.00K$1.18M$20.64M$31.28M$15.02M$420.00KN/AN/AN/A
    Long-term debt$1.96M$2.49M$2.96M$3.37MN/AN/AN/AN/A$0$0
    Shareholder equity$1.11B$1.13B$1.14B$1.27B$1.16B$569.39M$82.78M$51.15M$54.18M$54.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.08B$1.09B$1.16B$1.21B$1.21B$1.20B$1.21B$1.22B$1.23B$1.23B$1.23B$1.24B
    Total liabilities$94.22M$93.24M$112.22M$106.81M$93.81M$88.20M$82.97M$90.81M$98.86M$103.39M$103.24M$102.04M
    Cash and equivalents$86.79M$26.30M$23.40M$50.19M$117.64M$87.88M$67.28M$55.14M$58.04M$65.11M$54.68M$97.47M
    Shareholder equity$990.49M$1.00B$1.05B$1.11B$1.13B$1.12B$1.13B$1.13B$1.14B$1.13B$1.13B$1.14B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$101.64M$21.06M$27.00M$253.52M$538.58M$140.63M$5.52M-$675.00K$1.33M$4.41M
    Capital expenditures$22.57M$40.31M$22.21M$18.77M$23.81M$35.13M$1.18M$2.32M$2.90M$3.79M
    Free cash flow-$124.21M-$19.25M$4.80M$234.75M$514.76M$105.50M$4.33M-$3.00M-$1.56M$617.00K
    Dividends paidN/AN/AN/AN/A$4.16M$15.02MN/AN/A$0$4.75M
    Share repurchases$10.88M$225.00K$25.06M$74.34M$0$0N/AN/A$801.00K$11.98M
    Investing cash flow$111.37M-$58.35M$38.90M-$261.31M-$546.55M-$326.44M-$29.05M$950.00K-$2.05M-$42.80M
    Financing cash flow-$14.79M-$4.85M-$47.78M-$77.14M$85.41M$261.25M$28.77M$15.00K-$770.00K$45.79M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$109.23M-$23.76M$7.10M-$78.14M$11.11M-$30.17M-$4.43M$25.02M-$15.51M$4.29M$7.27M$14.93M
    Capital expenditures$1.79M$3.86M$5.20M$4.98M$6.05M$6.83M$4.72M$3.78M$19.54M$12.94M$4.06M$3.11M
    Free cash flow$107.44M-$27.62M$1.90M-$83.12M$5.06M-$37.00M-$9.15M$21.24M-$35.05M-$8.66M$3.21M$11.83M
    Last 12 quarters

    Frequently Asked Questions About FLGT

    What is Fulgent Genetics' annual revenue?

    Fulgent Genetics reported revenue of $322.67M for the fiscal year ended Dec 31, 2025.

    How fast is Fulgent Genetics' revenue growing?

    Revenue was up 13.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -19.5%.

    Is Fulgent Genetics profitable?

    No. Fulgent Genetics reported net income of -$61.63M for the fiscal year ended Dec 31, 2025, with a net margin of -19.1%.

    How much free cash flow does FLGT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$101.64M minus capital expenditures of $22.57M produced free cash flow of -$124.21M.

    How much debt does Fulgent Genetics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $1.96M, short-term debt of $476.00K and cash and equivalents of $50.19M.